EC Number   |
Application |
Reference |
|---|
    2.7.1.21 | diagnostics |
combined detection of the three tumor markers, serum alpha-L-fucosidase, alpha-fetoprotein and thymidine kinase 1 can play a complementary role in the diagnosis of hepatocellular carcinoma, and can significantly improve the sensitivity for the diagnosis of hepatocellular carcinoma |
750551 |
| 2.7.1.21 | diagnostics |
double immunostaining for thymidine kinase-1 (TK1)/CD31 can detect activated tumor vessels more accurately than staining for Ki67/CD31 and potentially could identify tumors that will respond to anti-angiogenic therapy |
758947 |
| 2.7.1.21 | diagnostics |
plasma thymidine kinase is a circulating prognostic marker in ER+//HER2- metastatic breast cancer patients treated with endocrine therapy and palbociclib |
758984 |
| 2.7.1.21 | diagnostics |
serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer |
760134 |
| 2.7.1.21 | medicine |
enzyme can be useful in gene therapy |
663222 |
| 2.7.1.21 | medicine |
enzyme is a target for antiviral therapy and treatment of EBV-associated malignancies |
661194 |
| 2.7.1.21 | medicine |
Hsv1-tk mutants are present in multiple ganglia of an immunocompromised patient with a history of chronic Acv(r) skin lesions. Mutations in the thymidine kinase gene of herpes simplex virus type 1 explain in most cases of the virus resistance to acyclvir treatment. Mutants arise independently under drug selection and establish latency in human sensory ganglia alone or together with the wild-type virus |
675714 |
| 2.7.1.21 | medicine |
mean serum TK1 activities in sera from myelodysplastic syndrome, breast and prostate cancer patients are 11, 6.7 and 1.8 pmol/min/ml, differing significantly from blood donors (mean value 1.1 pmol/min/ml). Serum TK1 protein levels are also significantly higher in myelodysplastic syndrome, breast, prostate cancer patients compared to blood donors. The detected active TK1 is primarily a high molecular weight complex, similar to the forms found in sera from myelodysplastic syndrome patients and blood donors. High TK1 25 kDa protein levels are found in fractions lacking TK1 activity in sera from cases with breast and prostate cancer |
737937 |
| 2.7.1.21 | medicine |
potential efficacy of the adenovirus-thymidine kinase/ganciclovir gene therapy approach as a viable nonsurgical alternative treatment for uterine leiomyomas |
686992 |
| 2.7.1.21 | medicine |
serum TK1 activity displays a statistically significant decline from young (18-35 years) to middle-aged (36-60 years) and further on to elderly (60-86 years) healthy individuals. Age-related reference range is: <30 U/l for young, <25 U/l for middle-aged and <19 U/l for elderly. There is no difference in TK1 activity between the studied healthy men and women. In chronic lymphocytic leukemia patients, TK1 activity is the highest in the advanced Rai stages. TK1 is significantly elevated in CD38+/Zap70+ chronic lymphocytic leukemia patients, and shows significant correlation with white blood cell and absolute B-cell count |
739508 |
